Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT ID: NCT01137643
Last Updated: 2025-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
15000 participants
OBSERVATIONAL
2009-07-31
2040-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Collection of Tissue Samples for Cancer Research
NCT00900198
Tissue Collection for Studies of Lymph Cancer
NCT01676805
Biology Studies of Hematologic Cancers
NCT00923442
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
NCT00900471
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies.
* Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies.
* Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research.
* Address medical and legal issues, and protect participant and patient privacy and confidentiality.
* Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers.
* Support young investigators to obtain pilot data for grant funding.
OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biologic sample preservation procedure
All samples collected during routine clinical care.
cytology specimen collection procedure
All Samples collected during routine clinical care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:
* Acute myeloid leukemia
* Acute lymphoblastic leukemia
* Chronic myelogenous leukemia
* Chronic lymphoid leukemia
* Non-Hodgkin lymphoma
* Hodgkin lymphoma
* Myelodysplastic syndromes
* Myeloproliferative disorders
* Multiple myeloma
* Waldenstrom macroglobulinemia
* Aplastic anemia
* Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage
* Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
UNC Lineberger Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Armistead, MD
Role: PRINCIPAL_INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tissue Procurement Facility
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Web address for UNC Lineberger Comprehensive Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000674072
Identifier Type: OTHER
Identifier Source: secondary_id
LCCC 0824
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.